Analyst nearly doubles price target between Gocovri pricing and better prospects in Multiple Sclerosis arena.
Lead asset for ADMS indicates promising prospects in Parkinson’s along with valuable opportunity in MS.
Irina Rivkind Koffler Doubles Down on Bearish Bet
Adamas Puts CRL Fears to Rest with Gocovri (Amantadine) Approval
Mizuho analyst Irina Rivkind Koffler came out today with new research notes on a handful of biotechnology stocks. Let’s take a look and …
Eagle Pharmaceuticals Inc (NASDAQ:EGRX) shares are on an almost 24% cave-in today after the biotech firm’s leading pipeline program, the one the Eagle …
Horizon Pharma PLC (NASDAQ:HZNP) investors scurried sending shares crashing 35% yesterday once the biotech firm released disappointing first quarter earnings for the year …
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) shares are tumbling 6% today on the heels of a debt refinancing reveal that could simultaneously lift interest …
Top analyst Irina Rivkind Koffler at Mizuho is all the more bullish on Endo International plc – Ordinary Shares (NASDAQ:ENDP) following the subdued …
Though Valeant Pharmaceuticals Intl Inc (NYSE:VRX) shares were surging nicely ahead at almost 6% yesterday, and continuing to rise today, top analyst Irina …